Call to Order and Welcome
Review of Minutes of Leiden MEETING 2012
Update on GCIG Rare Tumor Initiative (I Ray-Coquard & J Ledermann)
Update of rare gynecologic cancer GCIG meeting London Nov 2013 (I Ray-Coquard & J Ledermann)
New projects
Other Business
Adjournment
SUMMARY

Ov & Ut carcinosarcoma
low malignant potential tumors
low grade serous carcinoma
Sex cord tumor
germin Cell Tumor
squamous Ov carcinoma
Small Cell carcinoma cervix
small cell carcinoma OV
vulvar & vagina non squamous carcinoma
ovarian carcinoid tumor
pseudomixoma peritonei & mucinuous carcinoma
clear cell carcinoma Ovary
clear cell carcinoma Cervix & Ut
trophoblastic diseases
low grade endometrial stromal sarcoma
HG uterine sarcoma
uterine papillary serous carcinoma
adenosarcoma
Ut & Ov leiomyosarcoma
glandular carcinoma of cervix

20 DOCUMENTS:
18 sent at least a first draft (MEoc, BL waiting)
4 completely finalized
4 2nd draft waiting
7 under validation by group/chairs
3 under review by co coordonator
Questions & discussions

- Definition of the project:
  - GCIG rare tumor consensus review

- Relation with other groups/societies:
  - WSN, ISSTD, EOSTD, ..... 

- Next steps for publication:
  - Review by national groups will be done on Sept
  - Finalization by an “editing board” I R-C, JAL, M. Friedlander, K Lorusso, E Kohn, D Gershenson, A Oza for October
  - Final version posted on GCIG website

- Next meeting specifically dedicated to review documents ESMO meeting (Amsterdam 2013)
Participants: GCIG groups (2-3 representatives for each group) & invited speakers / experts in the field

Objectives:
- To define current guidelines for rare gynecologic tumors;
- To define control arm for present and future clinical trials involving rare cancer;
- To identify national & international barriers for trials dedicated to rare gynecologic cancers;
- To summarize and prioritize key issues for research and agree new set of trial concepts to address the key issues in several rare tumors;
- To prioritize and design 3 international initiatives in rare gynecologic cancer.
Welcome, objectives

Review & validation of the GCIG rare cancers documents

Main statistical issues for ongoing & future trials

Main harmonization/Regulation issues

Complexities of collecting samples across international boundaries -

Example of successful story from other cancers/groups

II part : 3 working groups sessions
  1) relatively rare tumors
  2) rare tumors
  3) very rare tumors
GCIG on ongoing trials or potential trials

- Alienor (GINECO)